Indian pharmaceutical major Ranbaxy Laboratories Ltd said Monday that it reached a settlement with British drug maker GlaxoSmithKline over possible patent litigation regarding a generic version of Glaxo's Imitrex tablets.

The settlement allows Ranbaxy to distribute the generic version of the drug, Sumatriptan Succinate Tablets in the United States starting at the expected launch date in December 2008.

Ranbaxy will be allowed to distribute the generic drug in sizes of 25mg, 50mg and 100mg.

Other terms of the agreement were not disclosed.

Researcher IMS estimates that the market for Imitrex was $985 million as of September 2007.